Lexeo net loss narrows to $25.9 million in Q2 FY26; R&D expenses rise to $19 million
LXEO•Pipeline update on LX2006
- Lexeo initiated SUNRISE-FA 2 for LX2006 in June.
- Topline data are expected in H2 2027, with a potential accelerated-approval BLA in H1 2028.
Second-quarter financial results
- Lexeo reported a Q2 2026 net loss of $25.9 million, narrowing from a $26.1 million loss a year earlier.
- Loss per share improved to $0.30 from $0.60 in the prior-year quarter.
- R&D expense rose 29.27% to $19 million, while G&A expense dropped 43.66% to $9 million.
- Cash, cash equivalents, and investments totaled $234.2 million at June 30, 2026, with runway expected into 2028.
Related News
AB InBev’s Stella Artois partners with Laver Cup as official beer for London 2026 event
BUD•
Protalix publishes corporate presentation highlighting Elfabrio commercialization and PRX-115 Phase 2 gout study
PLX•
